2015
DOI: 10.1016/j.molmed.2015.03.003
|View full text |Cite
|
Sign up to set email alerts
|

Tau immunotherapy for Alzheimer's disease

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

3
179
0
1

Year Published

2016
2016
2020
2020

Publication Types

Select...
7
1

Relationship

0
8

Authors

Journals

citations
Cited by 234 publications
(188 citation statements)
references
References 91 publications
3
179
0
1
Order By: Relevance
“…In transgenic mouse models, passive transfer of tau-specific antibodies can reduce tau pathology (20,(33)(34)(35). Similar approaches in humans are being widely studied as potential treatments for neurodegeneration (36). However, the mechanisms by which antibodies exert their activity is unclear.…”
Section: Discussionmentioning
confidence: 99%
“…In transgenic mouse models, passive transfer of tau-specific antibodies can reduce tau pathology (20,(33)(34)(35). Similar approaches in humans are being widely studied as potential treatments for neurodegeneration (36). However, the mechanisms by which antibodies exert their activity is unclear.…”
Section: Discussionmentioning
confidence: 99%
“…Although, our results suggest that CSF tau oligomers could be used as a potential biomarker in combination with the core biomarkers, additional studies, especially longitudinal ones, are required. Such studies are critical not only to diagnose the disease pathology more accurately, but also to prepare for evaluating the upcoming and exciting anti tau therapeutic approaches which have been initiated recently in clinical trials 42. Identifying novel CSF biomarkers for AD may supplement the traditional neuropsychological and imaging diagnostic techniques used for early diagnosis, and may become a useful surrogate for evaluating the pharmacological action of therapies targeting AD and other tau‐associated dementias.…”
Section: Discussionmentioning
confidence: 99%
“…In parallel, suppression of the neurodegenerative action of APN is required. Inhibition of tau aggregation may be an efficient strategy to inhibit sequestration of APN by tau, and a clinical study of tau immunization for progressive supranuclear palsy is ongoing 68. However, stimulating endogenous production of APN using compounds such as PPAR‐ γ agonists,69 acetylcholinesterase inhibitors,70 and vitamin E71 may be detrimental in terms of the toxic gain of function of APN.…”
Section: Apn As a Novel Target For Therapies For Admentioning
confidence: 99%